13F Holdings
中文EN

MMTZF MindMaze Therapeutics Holding SA IFRS Annual reports only

Pharmaceutical Preparations · OTC · SEC CIK 1854078 · Reporting currency CHF · Fiscal year ends 12/31

Financial factors as of 2023-12-31 (FY2023), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY-11.0%
TTM net income YoY-93.3%
TTM EPS YoY-73.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1,751.4%
Net margin-1,551.5%
FCF margin-285.4%
EBITDA margin-1,699.0%

Returns

ROE-99.4%
ROA-74.0%
ROIC (approx.)-106.4%
Asset turnover0.05x

Leverage & solvency

Liabilities / assets31.6%
Debt / equity0.01x
Current ratio2.65x
Interest coverage-116.78x

Cash quality & payout

Operating cash flow / net income0.18x
Accruals ratio-60.8%
Payout ratio—
Capex / revenue7.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Unit: CHF FY2023*2023-12-31FY2022*2022-12-31FY2021*2021-12-31
Income statement
Revenue6.33M7.11M4.49M
R&D expense1.33M12.39M19.02M
Operating income-110.83M-52.04M-34.31M
Interest expense949,0002.29M1.32M
Pretax income-111.68M-54.32M-35.52M
Income tax-13.50M-3.53M-820,000
Net income-98.18M-50.79M-34.70M
EBITDA-107.51M-48.18M-32.27M
EPS (basic)-8.35-4.80-0.01
EPS (diluted)-8.35-4.80-0.01
Weighted avg. shares (diluted)11.75M10.57M3.59B
Balance sheet
Cash & equivalents14.56M19.24M44.76M
Short-term investments9,00028,00028,000
Receivables1.17M1.32M1.30M
Inventory557,000227,000391,000
Current assets18.30M22.58M54.97M
PP&E, netmay include right-of-use assets (IFRS)397,00049,00038,000
Intangibles54.41M162.91M192.30M
Total assets76.39M188.80M251.62M
Current liabilities6.91M10.72M19.73M
Short-term debt337,000372,00095,000
Long-term debt9,00016,000396,000
Total debt346,000388,000491,000
Total liabilities24.16M43.38M70.09M
Shareholders' equity52.23M145.42M181.53M
Net debt-14.21M-18.85M-44.27M
Cash flow statement
Operating cash flow-17.61M-24.13M-35.72M
Capital expenditure446,00033,000—
Free cash flow-18.06M-24.16M—
Investing cash flow8.70M-8.00M-30.26M
Financing cash flow4.05M6.42M67.69M
Depreciation & amortization3.32M3.86M2.04M
Stock-based compensation814,0002.19M1.14M

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· This company does not report gross profit in XBRL.

· Amounts are in the company's reporting currency, CHF, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.